Measles, Mumps, and Rubella Vaccine Not Linked to Autism Risk in Study of 2.5 Million Children
A new study tracking more than 2.5 million children provides clear evidence that receiving the measles, mumps, and rubella (MMR) vaccine before age two does not increase the risk of developing autism. Published in The Pediatric Infectious Disease Journal, the research found that the precise timing of the routine immunization had no bearing on a child’s likelihood of receiving an autism diagnosis.
Autism spectrum disorder affects approximately 3.2 percent of children in the United States, impacting communication, social interaction, and how a person experiences the world. Persistent anxieties linking the standard MMR vaccine to the developmental condition often lead parents to delay or decline immunizations. This hesitancy traces back to a retracted 1998 case series of just 12 children, which was later invalidated due to scientific misconduct. Numerous large-scale investigations over the decades have contradicted those early fears.
Age-Anchored Landmark Analysis Addresses Observational Study Flaws
Observational vaccine safety studies face inherent design challenges. A family’s healthcare habits, early parental concerns about a child’s development, and the child’s age can influence both vaccination timing and diagnosis rates. To bypass these confounding variables, researchers led by Todd L. Burstain of UW Medicine utilized an age-anchored landmark analysis. This method groups children by the specific age window when vaccination decisions typically occur, comparing vaccinated and unvaccinated children directly within those windows to minimize bias.
The research team analyzed electronic health records from Cosmos, a vast database spanning hospitals and clinics across the United States. The dataset captured 2,560,035 children who attended at least one routine primary care visit between 12 and 24 months of age. Within this sample, the prevalence of childhood autism stood at 2.55 percent. Researchers focused specifically on a narrow diagnostic code for childhood autism rather than the broader spectrum, which explains why the sample’s prevalence fell below the national average. Investigators excluded children diagnosed with autism at or before 11 months of age to guarantee the vaccination occurred prior to the diagnosis.
Adjusted Hazard Ratios Confirm No Elevated Autism Risk
By 24 months of age, 91.4 percent of children in the cohort received their first dose of the MMR vaccine. The authors divided participants into discrete age windows, ranging from 11.5 to 12.5 months up to 24 months. Within each window, they measured children receiving their first dose against peers who remained unvaccinated throughout the follow-up period, which extended up to age eight or December 2024.
To ensure a balanced comparison, analysts adjusted for maternal age, race, ethnicity, gestational age at birth, multiple births, gestational size, neighborhood disadvantage, and pregnancy-related conditions like diabetes or urinary tract infections. Across all evaluated windows, the first vaccine dose showed no association with an increased risk of autism. In the primary analysis covering vaccination between 11.5 and 24 months, the adjusted hazard ratio hit 0.97 with a 99 percent confidence interval of 0.91 to 1.03. Because this range encompasses 1.0, the data shows no statistically significant difference in risk between the two groups.
In two later windows—14.5 to 17.5 months and 17.5 to 24 months—vaccinated children recorded slightly lower rates of autism diagnosis, with hazard ratios of 0.90 and 0.92, respectively. The authors attributed these minor deviations to leftover statistical bias rather than any protective mechanism of the vaccine. Results remained stable under sensitivity tests, including models omitting neighborhood disadvantage data and analyses excluding children with only a single recorded autism diagnosis.
To validate their methodology, the researchers deployed a negative control exposure by examining the pneumococcal conjugate vaccine booster. Given around 12 to 15 months to prevent bacterial infections, this booster has no theoretical link to autism. The similar null result for the pneumococcal booster confirmed that the study design did not generate false signals tied to routine pediatric checkups.
Limitations and Missing Data Factors in Electronic Records
Despite the large sample size, the study relied on observational medical records, meaning researchers could not control for every unmeasured variable in a child's environment. The dataset notably lacked information regarding a family history of autism. If parents of an older autistic child systematically delay vaccinating younger siblings, this missing metric could skew the data to make the vaccine appear protective.
However, a cited 2015 study examining U.S. children with older autistic siblings similarly found no link between the MMR vaccine and autism. Vaccinated children in the cohort stayed engaged in the medical system significantly longer than unvaccinated peers, with a median follow-up of 853 days compared to 366 days. Greater interaction with healthcare providers typically creates more opportunities for a formal diagnosis, yet investigators still detected no elevated risk among the vaccinated population.
Worth a look